Alcohol Use Disorder (AUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Alcohol Use Disorder (AUD) Market Outlook
Thelansis’s “Alcohol Use Disorder
(AUD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Alcohol Use Disorder (AUD)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Alcohol Use Disorder (AUD) Overview
Alcohol
use disorder (AUD) is a pathological condition characterized by persistent and
excessive alcohol consumption, leading to a diminished ability to limit or
abstain from alcohol use despite adverse consequences in one’s social,
occupational, or medical domain. The disorder is characterized by several key
symptoms, including craving, which is an intense urge to consume alcohol; loss
of control, an inability to cease alcohol consumption once initiated; and a
negative emotional state, feelings of anxiety and irritability when abstaining
from alcohol. Several factors increase the chances of developing an alcohol use
disorder, such as family history of substance abuse and alcohol use disorder,
the accessibility of alcohol, excessive alcohol consumption, binge drinking,
permissive cultural attitudes toward alcohol, childhood abuse, childhood
conduct or mood disorders, co-occurring mental health conditions such as
depression and PTSD, and impulsivity.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment